Finance
Antidepressant Maker Seaport Raises $255 Million in Upsized IPO
Seaport Therapeutics Inc., a clinical-stage biotechnology company focused on antidepressants and anxiety drugs, raised nearly $255 million in an upsized US initial public offering that priced at the top of its marketed range.
B
Bloomberg
May 1, 2026·1 min read
Image: Bloomberg
Seaport Therapeutics Inc., a clinical-stage biotechnology company focused on antidepressants and anxiety drugs, raised nearly $255 million in an upsized US initial public offering that priced at the top of its marketed range.
Original article
Antidepressant Maker Seaport Raises $255 Million in Upsized IPO
Published by Bloomberg